Wound Infection Clinical Trial
— DRESSINgOfficial title:
A Randomised Controlled Trial to Assess the Clinical and Cost Effectiveness of Dialkylcarbamoylchloride (DACC) Coated Post-operative Dressings Versus Standard Care in the Prevention of Surgical Site Infection in Clean or Clean-contaminated, Vascular Surgery.
NCT number | NCT02992951 |
Other study ID # | R2034 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 19, 2017 |
Est. completion date | January 1, 2025 |
Surgical site infection is an infection at a place in the body where surgery has taken place, and has been reported in around 5% of people undergoing an operation. In vascular surgery, infection rates are as high as 30%. Methods to reduce this rate of infection should be investigated thoroughly for their effectiveness and cost-effectiveness. The investigators aim to conduct a research trial examining one such method. Leukomed Sorbact is a wound dressing coated with a chemical (DACC) derived from spider-silk that interacts with, and binds bacteria, causing them to be mechanically removed from a wound when the dressing is changed. The trial aims to compare the effectiveness of this dressing to a standard, non-coated dressing, in the reduction of surgical site infection. 718 patients from a number of centres across the UK will be recruited to this study. Adult patients who are having a vascular surgery operation will be approached for entry into the trial. The trial will be explained to them, as well as an explanation that participation is voluntary and their operation or other aspects of their care will not be impacted in any way should participants not wish to participate. Participants will be randomised by computer into one of two groups - one group whose wounds are dressed with Leukomed Sorbact, and the other whose wounds are dressed with a standard dressing. Patients will be followed up at 30 days post-operatively. At the follow up, their wounds will be inspected for infection, and participants will be asked to complete short questionnaires measuring quality of life. Quality of life will also be assessed at 3 months post surgery. The trial will aim to answer a number of questions, with the primary question being does a DACC coated dressing applied after an operation reduce the risk of an infection at the surgery site? It will also ask whether this treatment is cost-effective and whether it promotes satisfactory healing and evaluate the overall carbon footprint impact of each intervention. Studies Within a Trial will be conducted to validate a remote diagnostic measure for detecting surgical site infection using wound images and the Bluebelle Wound Healing Questionnaire, evaluate feasibility of novel hair removal methods such as epilation and waxing, carbon footprint modelling within randomised controlled trials.
Status | Recruiting |
Enrollment | 718 |
Est. completion date | January 1, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: In order to be eligible for inclusion in the study the participants must meet the following criteria: - Adults =18 yrs undergoing clean or clean-contaminated lower limb vascular surgery, with wounds closed by primary intention. - Able to understand the Patient Information Sheet and supplementary materials and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits and completing written questionnaires). Exclusion Criteria: Patients will not be included in the study if they meet any of the following exclusion criteria: - Patients on antibiotics for other conditions at the time of surgery or in the follow up period. - Patients undergoing any procedure that does not include lower limb incisions. - Allergies to any component of either the DACC-coated dressing or the control dressing. - Inability to give informed consent due to incapacity (as defined by the MCA 2005) - Aged under 18 years at the time of recruitment - Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Academic Vascular Surgery Unit, Vascular Laboratory, Alderson House, Hull Royal Infirmary | Hull | East Riding Of Yorkshire |
Lead Sponsor | Collaborator |
---|---|
Hull University Teaching Hospitals NHS Trust | University of Hull |
United Kingdom,
Totty JP, Harwood AE, Cai PL, Hitchman LH, Smith GE, Chetter IC. Assessing the effectiveness of dialkylcarbamoylchloride (DACC)-coated post-operative dressings versus standard care in the prevention of surgical site infection in clean or clean-contaminated, vascular surgery (the DRESSINg trial): study protocol for a pilot feasibility randomised controlled trial. Pilot Feasibility Stud. 2019 Jan 18;5:11. doi: 10.1186/s40814-019-0400-2. eCollection 2019. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | SWAT 1 Validation Acceptability | Response rates to measure at 30 and 37 days | 30 and 37 days | |
Other | SWAT 1 Validation reliability | Inter and intra rater reliability | 30 and 37 days | |
Other | SWAT 1 Validation Validity | Sensitivity, specificity, ROC analysis, AUC | 30 days | |
Other | SWAT 2 Hair Removal Feasibility | Safety/adverse events | 30 days | |
Other | Carbon Footprint Model Development | Healthcare resource use data, consumable item weights | 3 months | |
Primary | 30 day infection rate | Surgical Site Infection at 30 days post-op | 30 days | |
Secondary | 3 month infection rate | Surgical Site Infection at 3 months post-op (implant patients only) | 3 months | |
Secondary | Quality of Life (SF-36 V2) | Score ranging from 0-100, higher values indicating better health | 30 days, 3 months | |
Secondary | Quality of Life (EQ-5D-3L) | Score ranging from 5-15, higher scores indicating worse health | 30 days, 3 months | |
Secondary | Mortality | 30-day mortality | 30 days | |
Secondary | Bluebelle wound healing questionnaire | Score ranging 0-41, higher values indicating infection | Days 30 and 37 | |
Secondary | Carbon Footprint Analysis | Healthcare resource use data | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02905955 -
Vacuumtherapy After Venous Hybrid Procedures
|
Phase 4 | |
Not yet recruiting |
NCT02868372 -
Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine
|
N/A | |
Enrolling by invitation |
NCT02559453 -
Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds
|
N/A | |
Completed |
NCT02744144 -
Wound Bacterial Microbiota and Their Antibiotic Resistance
|
N/A | |
Active, not recruiting |
NCT01939145 -
Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation
|
Phase 4 | |
Completed |
NCT00998907 -
PDS*Plus and Wound Infections After Laparotomy
|
N/A | |
Completed |
NCT01141335 -
Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair
|
Phase 4 | |
Terminated |
NCT00654641 -
Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy
|
N/A | |
Completed |
NCT00576745 -
A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery
|
Phase 1 | |
Completed |
NCT00402727 -
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
|
Phase 3 | |
Recruiting |
NCT00150852 -
Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.
|
Phase 2 | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT04596124 -
Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze
|
N/A | |
Active, not recruiting |
NCT04584957 -
Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)
|
N/A | |
Recruiting |
NCT03960970 -
Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries
|
Phase 2 | |
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Completed |
NCT02018094 -
The Amputation Surgical Site Infection Trial (ASSIT)
|
Phase 4 | |
Terminated |
NCT03269968 -
Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery
|
N/A | |
Enrolling by invitation |
NCT02945761 -
High Concentration of Sugar Solution Irrigation Promotes the Healing of Infected Wound
|
N/A | |
Not yet recruiting |
NCT02882360 -
Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum
|
Phase 4 |